TYP · ASX

Tryptamine Therapeutics Limited (ASX:TYP)

AU$0.033

 -0.002 (-5.714%)
ASX:Live
14/03/2025 04:10:37 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

TYP Overview

TYP Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

TYP Price Chart

Key Stats

Market Cap

AU$21.64M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.0

Trade Value (12mth)

N/A

1 week

0%

1 month

-14.63%

YTD

-18.6%

1 year

27.27%

All time high

N/A

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Industrials

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

N/A

Short Sell (% of issue)

N/A

TYP Announcements

Latest Announcements

Date Announcements

27 February 25

Appendix 4D and Half Year Report for period 31 Dec 2024

×

Appendix 4D and Half Year Report for period 31 Dec 2024

13 February 25

Update - Proposed issue of securities - TYP

×

Update - Proposed issue of securities - TYP

13 February 25

2024 EGM Letter of Access, Notice of Meeting and Proxy

×

2024 EGM Letter of Access, Notice of Meeting and Proxy

30 January 25

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

16 January 25

Change of Director's Interest Notice - MD

×

Change of Director's Interest Notice - MD

16 January 25

Change of Director's Interest Notice - JC

×

Change of Director's Interest Notice - JC

16 January 25

Change of Director's Interest Notice - GJ

×

Change of Director's Interest Notice - GJ

16 January 25

Change of Director's Interest Notice - CN

×

Change of Director's Interest Notice - CN

16 January 25

Notification of cessation of securities - TYP

×

Notification of cessation of securities - TYP

15 January 25

Biotech Showcase 2025 Presentation

×

Biotech Showcase 2025 Presentation

06 January 25

Change of Auditor

×

Change of Auditor

18 December 24

Positive interim results in Phase 2a TRP-8802 IBS trial

×

Positive interim results in Phase 2a TRP-8802 IBS trial

16 December 24

Phase 1b extension results meet study objectives

×

Phase 1b extension results meet study objectives

04 December 24

Change of Director's Interest Notice - GJ

×

Change of Director's Interest Notice - GJ

04 December 24

Change of Director's Interest Notice - MD

×

Change of Director's Interest Notice - MD

04 December 24

Change of Director's Interest Notice - JC

×

Change of Director's Interest Notice - JC

04 December 24

Change of Director's Interest Notice - CN

×

Change of Director's Interest Notice - CN

02 December 24

Notification regarding unquoted securities - TYP

×

Notification regarding unquoted securities - TYP

29 November 24

Completion of Phase 1b study of TRP-8803 in obese subjects

×

Completion of Phase 1b study of TRP-8803 in obese subjects

22 November 24

First patient dosed in Phase 1b study into obese subjects

×

First patient dosed in Phase 1b study into obese subjects

19 November 24

Phase 1b determines optimal parameters for TRP-8803 use

×

Phase 1b determines optimal parameters for TRP-8803 use

12 November 24

Application for quotation of securities - TYP

×

Application for quotation of securities - TYP

12 November 24

Proposed issue of securities - TYP

×

Proposed issue of securities - TYP

12 November 24

Prospectus

×

Prospectus

08 November 24

Initial Director's Interest Notice - DT

×

Initial Director's Interest Notice - DT

TYP Fundamentals

Per Share Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) AU$ Lock Lock Lock Lock -0.14 -0.04 -0.01 Lock Lock Lock
EPS (Fully Diluted) AU$ Lock Lock Lock Lock -0.14 -0.04 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.0 70.4 71.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS AU$ Lock Lock Lock Lock -0.21 -0.14 -0.00 Lock Lock Lock
FCFPS AU$ Lock Lock Lock Lock -0.14 -0.03 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.7 36.6 97.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -47.6 -144.3 -56.4 Lock Lock Lock
DPS AU$ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS AU$ Lock Lock Lock Lock 0.12 -0.11 0.00 Lock Lock Lock
BPS (Tangible) AU$ Lock Lock Lock Lock 0.12 -0.12 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -54.3 -197.5 104.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 71 139 507 Lock Lock Lock
Basic m Lock Lock Lock Lock 71 139 507 Lock Lock Lock

Financial Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -100.0 N/A Lock Lock Lock
Selling & General Expenses AU$m Lock Lock Lock Lock 12 5 5 Lock Lock Lock
Gross Income AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 100.0 N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA AU$m Lock Lock Lock Lock -12 -5 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.2 59.1 2.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -12,417.6 N/A N/A Lock Lock Lock
Depreciation & Amortisation AU$m Lock Lock Lock Lock 2 0 0 Lock Lock Lock
EBIT AU$m Lock Lock Lock Lock -14 -5 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.4 64.1 2.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -14,150.7 N/A N/A Lock Lock Lock
Pretax Income AU$m Lock Lock Lock Lock -14 -6 -7 Lock Lock Lock
Income Taxes AU$m Lock Lock Lock Lock -4 0 -1 Lock Lock Lock
Net Income AU$m Lock Lock Lock Lock -10 -6 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.1 41.9 -4.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -10,111.3 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow AU$m Lock Lock Lock Lock -9 -4 -6 Lock Lock Lock
Capital Expenditures AU$m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow AU$m Lock Lock Lock Lock -1 0 2 Lock Lock Lock
Net Financing Cash Flow AU$m Lock Lock Lock Lock 2 2 9 Lock Lock Lock
Free Cash Flow AU$m Lock Lock Lock Lock -10 -4 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -2.2 58.6 -49.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -97.4 N/A N/A Lock Lock Lock
Franking Balance AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments AU$m Lock Lock Lock Lock 5 0 5 Lock Lock Lock
Total Assets AU$m Lock Lock Lock Lock 14 1 7 Lock Lock Lock
Long Term Debt AU$m Lock Lock Lock Lock 0 2 0 Lock Lock Lock
Net Debt AU$m Lock Lock Lock Lock -1 2 -5 Lock Lock Lock
Total Liabilities AU$m Lock Lock Lock Lock 5 5 2 Lock Lock Lock
Equity AU$m Lock Lock Lock Lock 9 -4 6 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 9 -2 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -53.6 -120.8 397.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -74.1 -785.5 -82.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -114.5 136.4 -109.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -86.2 -95.3 -88.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -70.1 -162.2 -126.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -59.8 -111.5 -123.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -152.5 -6.4 -9.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.1 -0.4 1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -12.7 -45.6 -95.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.1 0.2 3.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.1 0.2 3.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 51.2 80.5 75.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -192.6 -178.9 -327.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 215.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -14,185.7 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -103.9 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -74.1 -785.5 -82.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.5 -0.2 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -114.5 136.4 -109.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -114.5 136.4 -109.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 15,287.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 15,287.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 0.0 35,096.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 15,287.0 0.0 -35,096.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

TYP Shortsell

Frequently Asked Questions

The current share price of Tryptamine Therapeutics Limited (TYP:ASX) is AU$0.033.
The 52-week high share price for Tryptamine Therapeutics Limited (TYP:ASX) is AU$0.00.
The 52-week low share price for Tryptamine Therapeutics Limited (TYP:ASX)? is AU$0.00.
Tryptamine Therapeutics Limited (TYP:ASX) does not pay a dividend.
Tryptamine Therapeutics Limited (TYP:ASX) does not pay a dividend.
Tryptamine Therapeutics Limited (TYP:ASX) does not offer franking credits.
Tryptamine Therapeutics Limited (TYP:ASX) is classified in the Industrials.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.